Catalog No.
YHJ88801
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Gly241-Glu460
Predicted molecular weight
27.95 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q9Y5C1
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
ANG-5, Angiopoietin-like protein 3, ANGPT5, Angiopoietin-5, ANGPTL3, Angiopoietin-related protein 3
Proteogenomic and observational evidence implicate ANGPTL4 as a potential therapeutic target for colorectal cancer prevention., PMID:40511612
Circulating protein biomarkers and their association with vulnerable plaque characteristics - a PROSPECT II substudy., PMID:40503438
Hepatic Inactivation of Carnitine Palmitoyltransferase 1a Lowers ApoB-Containing Lipoproteins in Mice., PMID:40501382
A multivariable cis-Mendelian randomization method robust to weak instrument bias and horizontal pleiotropy bias., PMID:40471990
ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosis., PMID:40467521
Bridging systemic metabolic dysfunction and Alzheimer's disease: the liver interface., PMID:40437610
Unveiling the PGAM5-ANGPTL3 Axis: Implications for Atherosclerosis Progression and Therapy., PMID:40436528
Phosphoglycerate Mutase 5 Is Important Mediator for Instigating Arterial Lipid Accumulation and Aggravating Atherosclerosis., PMID:40436527
Mediating Role of the ANGPTL3/TFPI Protein Ratio in Regulating T-Cell Surface Glycoprotein CD5 Levels on Knee Osteoarthritis (KOA): A Mendelian Randomization Study., PMID:40429617
Evinacumab and reduced lipoprotein apheresis in pediatric homozygous familial hypercholesterolemia: a retrospective study on LDL-C., PMID:40393255
Angiopoietin-Like Protein 3 Inhibition: A Key to Silencing Residual Lipid Risk?, PMID:40368573
Angiopoietin-like protein inhibitors: Promising agents for the treatment of familial hypercholesterolemia and atherogenic dyslipidemia., PMID:40344904
Angiopoietin-Like Protein Family-Mediated Functions in Modulating Triglyceride Metabolism and Related Metabolic Diseases., PMID:40302331
Genetics of remnant cholesterol., PMID:40277396
Novel Therapeutics for Familial Chylomicronemia Syndrome., PMID:40257687
The significance of ANGPTL3 and ANGPTL4 proteins in the development of dyslipidemia in Type 2 diabetes mellitus., PMID:40256107
Durability and efficacy of solbinsiran, a GalNAc-conjugated siRNA targeting ANGPTL3, in adults with mixed dyslipidaemia (PROLONG-ANG3): a double-blind, randomised, placebo-controlled, phase 2 trial., PMID:40179932
Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally Controlled Hyperlipidemia: A Phase 2 Study., PMID:40167414
Beyond LDL: Targeting ANGPTL3 to Reduce Residual Cardiovascular Risk., PMID:40167412
Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and Early Human Studies., PMID:40158211
In vivo base editing of Angptl3 via lipid nanoparticles to treat cardiovascular disease., PMID:40129501
ANGPTL3/8 is an atypical unfoldase that regulates intravascular lipolysis by catalyzing unfolding of lipoprotein lipase., PMID:40112106
Depletion of Hepatic SREBP2 Protects Against Hypercholesterolemia and Atherosclerosis through the ANGPTL3-LPL Axis., PMID:40106311
Evaluating the Cardiometabolic Efficacy and Safety of Lipoprotein Lipase Pathway Targets in Combination With Approved Lipid-Lowering Targets: A Drug Target Mendelian Randomization Study., PMID:40052268
Treatment With Evinacumab Links a New Pathogenic Variant in the LPL Gene to Persistent Chylomicronemia., PMID:40046103
Remnant Cholesterol and Residual Risk of Atherosclerotic Cardiovascular Disease., PMID:40026498
Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review., PMID:40005962
RNA therapeutics in cardiovascular medicine., PMID:39998478
Evinacumab as an adjunct to lipid apheresis in an infant with homozygous familial hypercholesterolemia., PMID:39970166
Novel RNA-Based Therapies in the Management of Dyslipidemias., PMID:39940794
ANGPTL3 regulates the peroxisomal translocation of SmarcAL1 in response to cell growth states., PMID:39934259
Genetic insights of lipid metabolism and lipid-lowering drugs with Lewy body dementia risk: Evidence from Mendelian randomization., PMID:39929371
Efficacy of a novel PCSK9 inhibitory peptide alone and with evinacumab in a mouse model of atherosclerosis., PMID:39909173
The association of lipids and novel non-statin lipid-lowering drug target with osteoporosis: evidence from genetic correlations and Mendelian randomization., PMID:39893413
Multilayer regulation of postprandial triglyceride metabolism in response to acute cold exposure., PMID:39892721
Lipid Profile, PCSK9, ANGPTL3 and Lipoprotein (a) Levels in Men Diagnosed With Localized High-Grade Prostate Cancer and Men At-Risk of Prostate Cancer., PMID:39888285
Circulating ANGPTL3/8 Concentrations Are Associated With an Atherogenic Lipoprotein Profile and Increased CHD Risk in Swedish Population-Based Studies., PMID:39882603
Genetic association analysis of lipid-lowering drug target genes in chronic kidney disease., PMID:39877840
Blocking ANGPTL3 and CD47 impact on atherosclerosis-correspondence., PMID:39818262
Exploring emerging pharmacotherapies for type 2 diabetes patients with hypertriglyceridemia., PMID:39794291
Identifying Biomarkers for Atherosclerosis via Gene Expression and Biological Networking., PMID:39773060
Vaccination as a Promising Approach in Cardiovascular Risk Mitigation: Are We Ready to Embrace a Vaccine Strategy?, PMID:39766344
Cutting-edge lipid-lowering pharmacological therapies: Improving lipid control beyond statins., PMID:39765369
Prioritizing protein targets for dyslipidaemia and cardiovascular diseases using Mendelian randomization in South Asians., PMID:39763524
Identification and Evaluation of Angiogenesis-Related Proteins That Predict Major Adverse Cardiovascular Events in Patients with Peripheral Artery Disease., PMID:39728292
ANGPTL3 overcomes sorafenib resistance via suppression of SNAI1 and CPT1A in liver cancer., PMID:39708716
Genetic correlation between genes targeted by lipid-lowering drugs and venous thromboembolism: A drug-target Mendelian randomization study., PMID:39705479
Effects of Pemafibrate on LDL-C and Related Lipid Markers in Patients with MASLD: A Sub-Analysis of the PEMA-FL Study., PMID:39694503
Familial chylomicronemia: New perspectives., PMID:39672668
An up-to-date review of emerging biologic therapies for hypercholesterolemia., PMID:39668448
For research use only. Not for human or drug use.
